0001193125-26-149623
SEC filingCardiff Oncology appointed three new executives, including Dr. Mani Mohindru as permanent President and CEO, to strengthen its leadership team for advancing its lead cancer therapy onvansertib.
Cardiff Oncology has solidified its executive leadership with three key appointments, most notably transitioning Dr. Mani Mohindru from Interim CEO to permanent President and CEO. This move provides continuity as she has been leading the company and will continue serving on the Board. The company simultaneously appointed two experienced industry veterans: Josh Muntner as CFO brings over 25 years of biopharma finance experience including previous CFO roles at Imvax and Mesoblast, while Dr. Ajay Aggarwal as COO brings more than 15 years of pharmaceutical industry experience with clinical development expertise from roles at Aclaris Therapeutics, CereXis, Insmed, and AstraZeneca. The compensation packages for all three executives include substantial base salaries and significant equity components, with Muntner receiving an inducement grant under Nasdaq rules. Management stated these appointments reflect Cardiff's commitment to building an experienced team to advance onvansertib, the company's lead PLK1 inhibitor currently in Phase 2 trials for RAS-mutated metastatic colorectal cancer.